IBRX250117P3500
- 1.00
- 0.000.00%
ImmunityBio Newsroom
Express News | Immunitybio Announces Permanent J-Code (J9028) for Anktiva® Is Now Effective
Express News | D. Boral Capital Served as Co-Manager to Immunitybio, Inc. (Nasdaq: Ibrx) in Connection With Its $100.0 Million Underwritten Public Offering
What's Going On With ImmunityBio Shares Wednesday?
US Consumer Prices Rise in Line With Expectations in November as US Equity Futures Rise Pre-Bell
Macy's, Dave & Buster's, Bausch + Lomb And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Top Premarket Decliners
ImmunityBio Shares Down on Plans for Public Offering
Why Stitch Fix Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket
Express News | Immunitybio, Inc. Announces Proposed Public Offering of Common Stock
10 Health Care Stocks With Whale Alerts In Today's Session
Immunitybio Inc. (IBRX): Among the Most Promising Cancer Stocks According to Hedge Funds
Catalyst Watch: Robotaxi IPO, OPEC+, Holiday Shopping Data, and Movie Blockbusters
ImmunityBio And NCartes Enter Collaboration Agreement Aimed At Automating And Streamlining The Data Fulfillment Process For Clinical Trials; The Goal Of The Collaboration Is To Make This Essential Process Easier, Faster, And Less Expensive For...
Express News | Immunitybio and Ncartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment
ImmunityBio and NCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment
Sector Update: Health Care
ImmunityBio Shares Rise After 'Significant' Update on Bladder Cancer Treatment
High Quality 'SMID-cap' Stocks With Cyclical Exposure – MS
ImmunityBio Completes ANKTIVA's Post-Approval Enrollment Of The 100th Patient In BCG Unresponsive NMIBC CIS Trial And Reports A Complete Response Rate Of 71% With A Durable Duration Of Response Ranging Up To 54 Months Reported For 82 Patients...
Express News | Immunitybio Inc - Data to Be Submitted to EMA in Q4 2024